Raymond James Maintains Outperform on Leap Therapeutics, Raises Price Target to $18.5
Portfolio Pulse from richadhand@benzinga.com
Raymond James analyst Steven Seedhouse maintains an Outperform rating on Leap Therapeutics (NASDAQ:LPTX) and raises the price target from $17 to $18.5.
July 13, 2023 | 8:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has maintained an Outperform rating on Leap Therapeutics and raised the price target from $17 to $18.5, indicating a positive outlook for the stock.
The raised price target by Raymond James indicates a positive outlook for Leap Therapeutics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100